Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.34 |
| ▸ | ADCYAP1R1 | P41586 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 3/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21307058 | 1.00 | SCN9A (0.40) | SCN9AMGLLFFAR1HCRTR2ADCYAP1R1 | |
| SCHEMBL21294928 | 0.84 | HTR2C (0.43) | SCN9A | |
| SCHEMBL21294734 | 0.84 | HTR2C (0.43) | SCN9A | |
| SCHEMBL21306739 | 0.84 | HTR2C (0.43) | SCN9A | |
| SCHEMBL23140838 | 0.77 | NOTUM (0.40) | MGLLFFAR1HCRTR2ADCYAP1R1CETP | |
| Hydrochloric Acid SCHEMBL23140831 | 0.76 | NOTUM (0.39) | MGLLFFAR1HCRTR2ADCYAP1R1CETP | |
| SCHEMBL15937573 | 0.73 | HTR2C (0.42) | MGLLHCRTR2ADCYAP1R1DHODHNOTUM | |
| SCHEMBL14846072 | 0.73 | HTR2C (0.42) | MGLLHCRTR2ADCYAP1R1DHODHNOTUM | |
| SCHEMBL21311899 | 0.71 | PIM1 (0.38) | FFAR1HCRTR2ADCYAP1R1 | |
| SCHEMBL23639040 | 0.71 | TAS1R3 (0.44) | SCN9AFFAR1HCRTR2DHODHNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| CN-112041313-A | Pyridine-sulfonamide compounds and their use against pain and related conditions | 基因泰克公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | ASAH2, ACER2, PCSK9 | SCN9A 2136/4885MGLL 2438/4885FFAR1 3674/4885 |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | TRPV1, HCN4, TRPA1 | SCN9A 90/4885MGLL 3322/4885FFAR1 3846/4885 |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | TRPV1, HCN4, TRPA1 | SCN9A 90/4885MGLL 3322/4885FFAR1 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.